top of page
Clinically Proven Joint Health Support

Walking. Shopping. Climbing stairs. Household chores. Q-actin™ supports joint flexibility, strength and comfort so individuals can more easily perform these and other everyday activities. These are the results of clinical studies evaluating Q-actin versus a placebo or glucosamine-chondroitin. Remarkably, in both studies, only 20 mgs of Q-actin was required to achieve significant improvements in joint health and function.


Q-actin Joint Function and Mobility

A recent clinical study in 91 adults with moderate joint health issues demonstrated Q-actin improved joint function and mobility significantly better than a placebo. The results were published in Current Rheumatology Reviews.


The study enrolled 101 subjects with moderate osteoarthritis, 91 of which were evaluable. Subjects were divided into three groups taking a placebo or 20 mgs or 100 mgs of Q-actin daily for six months. Following a baseline evaluation, subjects were evaluated at 30-day intervals using three clinically valid analytical models: the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Visual Analogue Scale (VAS) and Lequesne's Functional Index (LFI).


Both Q-actin groups experienced significant reductions in pain and improvements in other joint function parameters at every point of the study by every evaluation method.  The Q-actin health benefits were dose dependent.


Q-actin Outperforms Glucosamine-Chondroitin

A randomized, double-blinded clinical study published in the Clinical Interventions in Aging demonstrated Q-actin was significantly more effective than glucosamine-chondroitin in relieving knee discomfort and increasing mobility.


The three-country study evaluated 122 men and women ages 40-75 with moderate joint health issues related to age. Study participants consumed either 1,350 mg of glucosamine-chondroitin or 10 mgs of Q-actin twice daily for six months.


Individuals were evaluated at 30, 60, 90, 120 and 180 days using WOMAC, VAS and LFI. Q-actin subjects reported significant joint health improvements at every evaluation period, compared with glucosamine-chondroitin.


The study demonstrates the ability of Q-actin to help restore, maintain and protect joint health, which is critical to older adults, elite and recreational athletes, and people struggling with body weight issues.


This study was published in the Clinical Interventions in Aging.

Only 20 mgs of
Q-actin daily produced clinically
significant improvements in joint function by every measure -- WOMAC, VAS and LIF.
Q-actin reduces WOMAC score 70% over 6 months in a direct clinical comparison with glucosamine/ chondroitin.
Study graph showing Q-actin outperforming glucosamine-chondroitin
bottom of page